Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemia.

doi:10.1016/j.ebiom.2024.105316

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemia.

EBioMedicine - 1 Oct 2024

Borek Weronika E, Nobre Luis, Pedicona S Federico, Campbell Amy E, Christopher Josie A, Nawaz Nazrath, Perkins David N, Moreno-Cardoso Pedro, Kelsall Janet, Ferguson Harriet R, Patel Bela, Gallipoli Paolo, Arruda Andrea, Ambinder Alex J, Thompson Andrew, Williamson Andrew, Ghiaur Gabriel, Minden Mark D, Gribben John G, Britton David J, Cutillas Pedro R, Dokal Arran D

Abstract excerpt

BACKGROUND: Acute myeloid leukaemia (AML) is a bone marrow malignancy with poor prognosis. One of several treatments for AML is midostaurin combined with intensive chemotherapy (MIC), currently approved for FLT3 mutation-positive (FLT3-MP) AML. However, many patients carrying FLT3 mutations are refractory or experience an early relapse following MIC treatment, and might benefit more from receiving a different...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Phosphoproteins

Share to Proteomics

Share to Staurosporine

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 39293215
DOI: 10.1016/j.ebiom.2024.105316
PMCID: PMC11424955

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemia.PMID 39293215Read ↗

Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemiaSemantic proximity Read ↗

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.Semantic proximity Read ↗

Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia.Semantic proximity Read ↗

Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort.Semantic proximity Read ↗

Proteomics and Phosphoprotoemic Measurements Enhance Ability to Predict Ex Vivo Drug Response in AMLSemantic proximity Read ↗

Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AMLSemantic proximity Read ↗

Proteomic Characterization of Acute Myeloid Leukemia for Precision MedicineSemantic proximity Read ↗

Multi-omics integration reveals immune hallmarks and biomarkers associated with FLT3 inhibitor sensitivity in FLT3-mutated AMLSemantic proximity Read ↗

Phosphoproteomics identifies determinants of PAK inhibitor sensitivity in leukaemia cellsSemantic proximity Read ↗

Integrated proteogenomic and metabolomic profiling of acute myeloid leukemias to identify molecular subtypes and associated therapy targets.Semantic proximity Read ↗

Early response evaluation by single cell signaling profiling in acute myeloid leukemiaSemantic proximity Read ↗

Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.